Elan

  • Is This Healthcare Stock Underrated?

    By Leo Sun - August 16, 2013 | Tickers: ELN, GSK, JNJ, PRGO, TEVA

    Shares of Perrigo Company (NYSE: PRGO), one of the world’s largest healthcare suppliers, slid with the broader market on August 15, after the company reported fourth quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (NYSE: ELN), which redcued its corporate tax rate by moving its more »

  • This Deal Could Shake Up the Generic Drug Business

    By Mike Thiessen - August 8, 2013 | Tickers: ACT, ELN, PRGO

    Many market-watchers are scratching their heads about the pharmaceutical industry's latest blockbuster deal. Although it had been expected to make such a move for some time, Perrigo Company (NYSE: PRGO) is not regarded as the "ideal" buyer for Dublin-based Elan (NYSE: ELN). Both firms operate as generic drug-makers, but the synergies between the two are not immediately obvious. 

    Moreover, Elan is coming off of a long, painful battle to more »

  • Will This Be the Next Irish Biotech Acquisition?

    By Brian Nichols - August 7, 2013 | Tickers: ELN, JAZZ, PRGO

    Perrigo Company’s (NYSE: PRGO) acquisition of Elan (NYSE: ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying a high U.S. corporate tax rate. Analysts believe that Perrigo’s acquisition represents a shift where companies are seeking assets in low taxed countries to increase profitability. According to analysts, there were several companies that were bidding to acquire Elan, but more »

  • This Merger Adds Value Multiple Ways

    By Mohsin Saeed - August 5, 2013 | Tickers: ELN, PRGO, PG

    2013 is turning out to be a stellar year for Mergers and Acquisitions. There have been a number of M&A deals in healthcare and technology sectors. Technology sectors might be in the news more often, but it’s the healthcare sector which has the highest number of M&As. During the current year, there have already been 426 confirmed deals. There were 203 M&As in the first quarter more »

  • Examining an Acquisition That Benefits This Global Healthcare Supplier

    By Anh HOANG - August 5, 2013 | Tickers: BIIB, ELN, PRGO

    Recently, Elan Corporation (NYSE: ELN) ended the fight against bids from Royalty Pharma. Previously, Royalty Pharma had raised its all-cash offer from $5.7 billion to $6.4 billion. Elan still thinks that Royalty Pharma’s offer continued to “grossly undervalue its current business platform and its future prospects, however. Instead, Elan went for an $8.6 billion offer of Perrigo Company (NYSE: PRGO).

    Perrigo’s business snapshot

    Perrigo has more »

  • Is This Acquisition a Game Changer?

    By Awais Iqbal - August 5, 2013 | Tickers: ACT, ELN, PRGO

    A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline. Either conduct research and organically develop the medicine, or acquire a company with a strong pipeline. The latter option is what Perrigo (NYSE: PRGO) recently opted for by acquiring Elan (NYSE: ELN). Additionally, Perrigo looks forward to increasing its international presence with this more »

  • Should Companies Use Acquisitions and Financial Engineering to Reduce Corporate Taxes?

    By Leo Sun - August 2, 2013 | Tickers: ACT, AAPL, ELN, PRGO, WCRX

    Perrigo (NYSE: PRGO), an American company best known for selling generic medication, baby formula and nutritional supplements, recently acquired Irish drugmaker in Elan (NYSE: ELN) for $8.6 billion in an unexpected deal that initially left investors puzzled. After all, what would Perrigo gain by acquiring Elan, a biotech primarily focused on experimental treatments for neurodegenerative and autoimmune diseases? The answer was simple - lower tax rates.

    A big buy for more »

  • 3 Pharma Companies to Buy for the Long Run

    By Madhukar Dubey - July 1, 2013 | Tickers: BIIB, ELN, HSP, VRX

    According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion in 2012. To keep pace with the industry's growth, pharmaceutical companies are spending on research and development in order to develop new drugs, and are pursuing various expansion strategies. These companies are also looking to more »

  • What’s Next for Elan?

    By Diane Alter - July 1, 2013 | Tickers: BIIB, ELN, PRTA

    Elan's (NYSE: ELN) board unanimously rebuffed a $6.7 billion takeover offer from Royalty Pharma in early June and hired Citigroup to review “several corporate inquiries.” Things are starting to get very interesting. 

    “Both the board and executive management are aligned in exploring all opportunities that maximize the full value of the company for its shareholders,” Elan said in a statement. Apparently, it believes the company is worth much more »

  • Prothena is Still Undervalued

    By Michal Vladimirsky - June 27, 2013 | Tickers: BLUE, ELN, EPZM, PRTA, GEVA

    Prothena is an Elan spin-off company that has gone on an impressive run since it began trading on the NASDAQ in December 2012. Shares are up 72% YTD. Prothena develops antibody treatments for diseases caused by misfolded proteins or improper cell adhesion. Elan committed significant start-up capital to Prothena and the company had cash and cash equivalents of $119.6 million at the end of the first quarter 2013. Operating more »

  • Is Elan Pushing Its Luck?

    By Seth Robey - June 18, 2013 | Tickers: BIIB, ELN, THRX, TTHI

    Recently Elan's (NYSE: ELN) shareholders voted against management's proposal to invest $1 billion in Theravance (NASDAQ: THRX), a deal which a fellow Fool calculates to be ill conceived.  Shareholders also voted against the purchase of Austrian AOP Orphan Pharmaceuticals, as well as the sale of Alzheimer's drug ELND005.  Conversely, shareholders did vote in favor of a $200 million share repurchase program, effectively thwarting Royalty Pharmaceutical's attempts more »

  • Investors Should Vote 'No' on Billion-Dollar Deal

    By Brian Nichols - June 6, 2013 | Tickers: ELN, THRX

    The Institutional Shareholder Services is an independent proxy advisory service, and after a review of Elan Corp. (NYSE: ELN), they are suggesting that shareholders vote AGAINST the Theravance (NASDAQ: THRX) offer, the AOP Orphan acquisition, the divestment of ELND005, and the $200 million share buyback, on June 17.

    While many of these issues may be beneficial to shareholders, there is one that could be crippling to the company, and that more »

  • Value Investor Seth Klarman's Shakeups

    By Marshall Hargrave - May 22, 2013 | Tickers: AIG, BP, DTV, ELN, ORCL

    Seth Klarman's Baupost Group, led by the famed value investor and author of Margin of Safety, recently revealed its public equity portfolio in its quarterly filing with the SEC. Klarman founded Baupost in 1983, and now has assets under management of nearly $30 billion. Outlined below are five takeaways from Baupost's portfolio, which include some interesting additions (check out Klarman's cheap stock picks).

    Baupost kept BP (NYSE: BPmore »)

  • Flush With Cash, Elan Goes on a Buying Spree

    By Diane Alter - May 20, 2013 | Tickers: BIIB, ELN, NVS

    Call it the luck of the Irish.

    Prospects have been glum for Elan Corp (NYSE: ELN), but the Irish pharmaceutical company is showing some real promise.

    After suffering a serious setback last July, when results for bapineuzumab, an Alzheimer’s therapy in development with Pfizer and Johnson & Johnson, were disappointing, many questioned its survival as a stand alone company. 

    You see, the failure of that drug left Elan with just more »

  • Who Benefits From This Market Moving Biotechnology Partnership?

    By Brian Nichols - May 14, 2013 | Tickers: ELN, GSK, THRX

    Back towards the end of April 2013, Theravance (NASDAQ: THRX) surprised everyone when it announced plans to split into two separate companies. The two companies will split its independent biopharmaceuticals operations and its respiratory assets (including the recently approved BREO ELLIPTA) partnered with GlaxoSmithKline (NYSE: GSK). Since this announcement, news of yet another partnership with Elan (NYSE: ELN) might leave investors confused as to the direction of the company. My more »

  • Why Did This Biotech Soar?

    By Brandy Betz - May 13, 2013 | Tickers: ELN, GSK, THRX

    Theravance (NASDAQ: THRX) shares soared over 14% early Monday upon news that Elan (NYSE: ELN) will pay $1 billion for a  quartet of development stage respiratory drugs. The payment will give Elan a cut of potential future royalties to the drugs -- most of which Theravance developed with GlaxoSmithKline (NYSE: GSK).

    What does this deal mean for the companies involved -- and is Elan getting its money’s worth?

    COPD breathes easier more »

  • Buybacks, Takeovers and a Potentially Lucrative Drug

    By Mike Thiessen - April 24, 2013 | Tickers: BIIB, ELN, PFE

    Irish drug-maker Elan Pharmaceuticals (NYSE: ELN) has been at the center of fervent speculation from longs and shorts alike. After offloading a potential blockbuster drug called Tysabri to a smaller competitor, the company has been fighting off a takeover bid from privately held Royalty Pharma. While it is entirely possible that Elan will eventually agree to be taken private by Royalty, both companies have refused to compromise on key aspects more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corp. (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • Page 1 of 2